To market, to market
Turning good ideas into marketable inventions, innovations, and medicines is the goal of most research. Emory ranked first in commercialization revenues in 2005, according to a report released in February by the Association of University Technology Managers, with more than $585 million in licensing revenue.
That year, Emory sold its future royalties from the Emory-discovered HIV/AIDS drug Emtriva to Gilead Sciences and Royalty Pharma for a one-time payment of $525 million. Emtriva, along with another Emory-invented HIV/AIDS drug, Epivir, is among the most commonly used HIV/AIDS therapies.
Emory also created four start-up companies in 2005, executed thirty licenses, filed fifty-four new patent applications, and received issuance of seventeen U.S. patents. The University’s research spending totaled $345.7 million. During the past fifteen years, commercialized Emory research discoveries have resulted in revenues of more than $720 million to the University.
“Part of the mission of Emory University is to create, preserve, teach, and apply knowledge in the service of humanity, and our technology transfer program does exactly that,” says Todd Sherer, director of Emory’s Office of Technology Transfer. “Our robust pipeline includes world-class products in all stages of development and regulatory approval, and will continue to ensure that outstanding discoveries from our faculty become available for prevention, diagnosis, and treatment of disease, as well as other consumer needs.”
To learn more about Emory’s Office of Technology Transfer, go to www.emory.edu/EMORY_MAGAZINE/spring_2005/eureka.html.